Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Notice of Results

&

Analyst and Investor Presentations

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines, intends to announce results for the period ended 30 April 2023 on Thursday 31 August 2023.

Analyst Briefing, 09:30, Thursday 31 August 2023

A briefing for analysts will be held at 09:30 BST on the day of the results.

Analysts interested in attending OCTP's briefing should contact Acuitas Communications by emailing oct@acuitascomms.com or by calling 020 3745 0293.

Investor Presentation, 13:30, Thursday 31 August 2023

A live online presentation to existing and prospective shareholders will take place at 13:30 BST on Thursday 31 August via the Investor Meet Company platform.

Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 09:00 the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Oxford Cannabinoid Technologies Holdings plc via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Investors who already follow OCTP on the Investor Meet Company platform will automatically receive an invitation to the event.

The Directors of the Company accept responsibility for the content of this announcement.

ENDS

Enquiries:

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the U$ multi-billion global pain market.

OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with Phase I clinical trials, aimed at demonstrating safety and tolerability. Trial results are expected in Q3 2023. The global market for CIPN alone is currently valued at US$1.61bn and is forecast to reach US$2.37bn by the year 2027.

OCTP's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.